Volume 23, Issue 4 (7-2024)
JRUMS 2024, 23(4): 307-321 |
Back to browse issues page
Ethics code: IR.IAU.TNB.REC.1402.086
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bazargan E, Ashrafi F, Elham S T. Antibacteria and Antibiofilm Properties of Tetracycline Loaded Niosomes against Klebsiella Pneumoniae Isolates: A Laboratory Study. JRUMS 2024; 23 (4) :307-321
URL: http://journal.rums.ac.ir/article-1-7195-en.html
URL: http://journal.rums.ac.ir/article-1-7195-en.html
North Tehran Branch, Islamic Azad University
Abstract: (1047 Views)
Antibacteria and Antibiofilm Properties of Tetracycline Loaded Niosomes against Klebsiella Pneumoniae Isolates: A Laboratory Study
Elham Bazargan[1], Fatemeh Ashrafi[2], Elham Siasi Torbati[3]
Received: 05/11/23 Sent for Revision: 13/03/24 Received Revised Manuscript: 22/06/24 Accepted: 24/06/24
Background and Objectives: Biofilm production is one of the reasons for drug resistance in bacteria. The aim of the present study was to synthesize niosomal structures containing tetracycline antibiotic and determine its effect on Klebsiella pneumoniae drug-resistant isolates in an effective treatment system.
Materials and Methods: In this laboratory study, nanoniosomes containing tetracycline (Tet-Nio) were synthesized using the thin layer hydration method, and the morphological characteristics of drug release was investigated. MIC (Minimum inhibitory concentration), crystal violet, MBEC (Minimum biofilm eradication concentration) tests were used to investigate the antibacterial and anti-biofilm effects against Klebsiella pneumoniae strains under study exposed to free tetracycline and Tet-Nio, and the expression of mrkA gene in 10 isolates using was evaluated by real-time PCR test. One-way analysis of variance was used to analyze the data.
Results: Formulation No.2 with the particle size of 169.45±9.55 nm, polydispersity index (PDI) equal to 0.168±0.010, Zeta-potential equal to -24.55±1.63, entrapment efficacy equal to 75.31%±1.48%, and tetracycline drug release percentage in 48 hours equal to 45.34%±1.15% was chosen as the optimal formulation. The microbial test results showed that the Tet-Nio structure has more antibacterial effects than the free drug. Also, it was stated that the optimal formulation of Tet-Nio can significantly reduce the formation of biofilm in Klebsiella pneumoniae pathogenic bacteria by reducing the expression of the mrkA gene compared to the drug-treated group (p<0.001).
Conclusion: Niosomes containing tetracycline were able to inhibit biofilm formation in drug-resistant isolates of Klebsiella pneumoniae. Therefore, they can be used in clinical studies to deal with nosocomial infections caused by Klebsiella pneumoniae isolate.
Keywords: Niosome, Tetracycline, Klebsiella pneumoniae, Biofilm, Antibiotic resistance
Funding: This study did not received any funds.
Conflict of interest: None declared.
Ethical Considerations: The Ethics Committee of the Islamic Azad University, Tehran North Branch, approved the study (IR.IAU.TNB.REC.1402.086).
Authors’ Contributions:
- Conceptualization: Fatemeh Ashrafi
- Methodology: Fatemeh Ashrafi
- Data collection: Elham bazargan
Formal analysis: Elham siasi
Elham Bazargan[1], Fatemeh Ashrafi[2], Elham Siasi Torbati[3]
Received: 05/11/23 Sent for Revision: 13/03/24 Received Revised Manuscript: 22/06/24 Accepted: 24/06/24
Background and Objectives: Biofilm production is one of the reasons for drug resistance in bacteria. The aim of the present study was to synthesize niosomal structures containing tetracycline antibiotic and determine its effect on Klebsiella pneumoniae drug-resistant isolates in an effective treatment system.
Materials and Methods: In this laboratory study, nanoniosomes containing tetracycline (Tet-Nio) were synthesized using the thin layer hydration method, and the morphological characteristics of drug release was investigated. MIC (Minimum inhibitory concentration), crystal violet, MBEC (Minimum biofilm eradication concentration) tests were used to investigate the antibacterial and anti-biofilm effects against Klebsiella pneumoniae strains under study exposed to free tetracycline and Tet-Nio, and the expression of mrkA gene in 10 isolates using was evaluated by real-time PCR test. One-way analysis of variance was used to analyze the data.
Results: Formulation No.2 with the particle size of 169.45±9.55 nm, polydispersity index (PDI) equal to 0.168±0.010, Zeta-potential equal to -24.55±1.63, entrapment efficacy equal to 75.31%±1.48%, and tetracycline drug release percentage in 48 hours equal to 45.34%±1.15% was chosen as the optimal formulation. The microbial test results showed that the Tet-Nio structure has more antibacterial effects than the free drug. Also, it was stated that the optimal formulation of Tet-Nio can significantly reduce the formation of biofilm in Klebsiella pneumoniae pathogenic bacteria by reducing the expression of the mrkA gene compared to the drug-treated group (p<0.001).
Conclusion: Niosomes containing tetracycline were able to inhibit biofilm formation in drug-resistant isolates of Klebsiella pneumoniae. Therefore, they can be used in clinical studies to deal with nosocomial infections caused by Klebsiella pneumoniae isolate.
Keywords: Niosome, Tetracycline, Klebsiella pneumoniae, Biofilm, Antibiotic resistance
Funding: This study did not received any funds.
Conflict of interest: None declared.
Ethical Considerations: The Ethics Committee of the Islamic Azad University, Tehran North Branch, approved the study (IR.IAU.TNB.REC.1402.086).
Authors’ Contributions:
- Conceptualization: Fatemeh Ashrafi
- Methodology: Fatemeh Ashrafi
- Data collection: Elham bazargan
Formal analysis: Elham siasi
[1]- PhD Student in Microbiology, Dept. of Microbiology, Faculty of Biological Sciences, Tehran North Branch, Islamic Azad University, Tehran, Iran
[2]- Associate Prof., Dept. of Microbiology, Faculty of Biological Sciences, Tehran North Branch, Islamic Azad University, Tehran, Iran
(Corresponding Author) Tel: (021) 77319327, E-mail: mnfa.ashrafi@yahoo.com
(Corresponding Author) Tel: (021) 77319327, E-mail: mnfa.ashrafi@yahoo.com
[3]- Associate Prof., Dept. of Genetics, Faculty of Biological Sciences, Tehran North Branch, Islamic Azad University, Tehran, Iran
Type of Study: Research |
Subject:
Microbiology
Received: 2023/11/4 | Accepted: 2024/06/24 | Published: 2024/07/20
Received: 2023/11/4 | Accepted: 2024/06/24 | Published: 2024/07/20
References
1. Arcari G, Raponi G, Sacco F, Bibbolino G, Di Lella FM, Alessandri F, et al. Klebsiella pneumoniae infections in COVID-19 patients: a 2-month retrospective analysis in an Italian hospital. Int J Antimicrob Agents 2021; 57(1): 106245.
2. Serra-Burriel M, Keys M, Campillo-Artero C, Agodi A, Barchitta M, Gikas A, et al. Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis. PLoS One 2020; 15(1): e0227139.
3. Flores-Valdez M, Ares MA, Rosales-Reyes R, Torres J, Girón JA, Weimer BC, et al. Whole genome sequencing of pediatric Klebsiella pneumoniae strains reveals important insights into their virulence-associated traits. Front Microbiol 2021; 12: 711577.
4. Lev AI, Astashkin EI, Kislichkina AA, Solovieva EV, Kombarova TI, Korobova OV, et al. Comparative analysis of Klebsiella pneumoniae strains isolated in 2012–2016 that differ by antibiotic resistance genes and virulence genes profiles. Pathogens and global health 2018; 112(3): 142-51.
5. Provenzani A, Hospodar A, Meyer A, Leonardi Vinci D, Hwang E, Butrus C, et al. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents. Int J Clin Pharm 2020; 42: 1016-25.
6. Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev 2016; 80(3): 629-61.
7. Schroll C, Barken KB, Krogfelt KA, Struve C. Role of type 1 and type 3 fimbriae in Klebsiella pneumoniae biofilm formation. BMC Microbiol 2010; 10: 1-10.
8. Jagnow J, Clegg S. Klebsiella pneumoniae MrkD-mediated biofilm formation on extracellular matrix-and collagen-coated surfaces. Microbiology 2003; 149(9): 2397-405.
9. Wang Q, Chang C-s, Pennini M, Pelletier M, Rajan S, Zha J, et al. Target-agnostic identification of functional monoclonal antibodies against Klebsiella pneumoniae multimeric MrkA fimbrial subunit. The Journal of Infectious Diseases 2016; 213(11): 1800-8.
10. Ahmadi Z, Noormohammadi Z, Ranjbar R, Behzadi P. Prevalence of tetracycline resistance genes tet (A, B, C, 39) in Klebsiella pneumoniae isolated from Tehran, Iran. Iranian Journal of Medical Microbiology 2022; 16(2): 141-7.
11. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65(2): 232-60.
12. Saini A, Panwar D, Panesar PS, Bera MB. Encapsulation of functional ingredients in lipidic nanocarriers and antimicrobial applications: a review. Environ Chem Lett 2021; 19: 1107-34.
13. Abdelkader H, Wu Z, Al-Kassas R, Alany RG. Niosomes and discomes for ocular delivery of naltrexone hydrochloride: morphological, rheological, spreading properties and photo-protective effects. Int J Pharm 2012; 433(1-2): 142-8.
14. Rahmati M, Babapoor E, Dezfulian M. Amikacin-loaded niosome nanoparticles improve amikacin activity against antibiotic-resistant Klebsiella pneumoniae strains. World J Microbiol Biotechnol 2022; 38(12): 230.
15. Karbalaeiheidar H, Ashrafi F. Vancomycin-gingerol encapsulated niosomal formulation against carbapenem-resistant Klebsiella pneumoniae. Biomedical Materials 2023; 18(4): 045015.
16. Hetta HF, Ramadan YN, Al-Harbi AI, Ahmed AE, Battah B, Abd Ellah NH, et al. Nanotechnology as a promising approach to combat multidrug resistant bacteria: A comprehensive review and future perspectives. Biomedicines 2023; 11(2): 413.
17. Thabet Y, Elsabahy M, Eissa NG. Methods for preparation of niosomes: A focus on thin-film hydration method. Methods 2022; 199: 9-15.
18. Akbarzadeh I, Yaraki MT, Bourbour M, Noorbazargan H, Lajevardi A, Shilsar SMS, et al. Optimized doxycycline-loaded niosomal formulation for treatment of infection-associated prostate cancer: An in-vitro investigation. J Drug Deliv Sci Technol 2020; 57: 101715.
19. Ahmadi S, Seraj M, Chiani M, Hosseini S, Bazzazan S, Akbarzadeh I, et al. In vitro development of controlled-release nanoniosomes for improved delivery and anticancer activity of letrozole for breast cancer treatment. International Journal of Nanomedicine 2022; 17: 6233.
20. Mirzaie A, Peirovi N, Akbarzadeh I, Moghtaderi M, Heidari F, Yeganeh FE, et al. Preparation and optimization of ciprofloxacin encapsulated niosomes: A new approach for enhanced antibacterial activity, biofilm inhibition and reduced antibiotic resistance in ciprofloxacin-resistant methicillin-resistance Staphylococcus aureus. Bioorg Chem 2020; 103: 104231.
21. Haddadian A, Robattorki FF, Dibah H, Soheili A, Ghanbarzadeh E, Sartipnia N, et al. Niosomes-loaded selenium nanoparticles as a new approach for enhanced antibacterial, anti-biofilm, and anticancer activities. Sci Rep 2022; 12(1): 21938.
22. Scherr TD, Heim CE, Morrison JM, Kielian T. Hiding in plain sight: interplay between staphylococcal biofilms and host immunity. Front Immunol 2014; 5: 37.
23. De la Fuente-Núñez C, Reffuveille F, Fernández L, Hancock RE. Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol 2013; 16(5): 580-9.
24. Lister JL, Horswill AR. Staphylococcus aureus biofilms: recent developments in biofilm dispersal. Frontiers in cellular and infection microbiology 2014; 4: 178.
25. Hajiahmadi F, Alikhani MY, Shariatifar H, Arabestani MR, Ahmadvand D. The bactericidal effect of lysostaphin coupled with liposomal vancomycin as a dual combating system applied directly on methicillin-resistant Staphylococcus aureus infected skin wounds in mice. International Journal of Nanomedicine 2019: 5943-55.
26. Marandi A, Ashrafi F, Bakhtiari N. Preparation and Evaluation of Anti-Cancer Effect of Lactobacillus Casei-Containing Niosome on Breast Cancer Cells Viability. Iranian Journal of Science 2023; 47(4): 1029-38.
27. Cortesi R, Ravani L, Rinaldi F, Marconi P, Drechsler M, Manservigi M, et al. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes. Int J Pharm 2013; 440(2): 229-37.
28. Abdelaziz AA, Elbanna TE, Sonbol FI, Gamaleldin NM, El Maghraby GM. Optimization of niosomes for enhanced antibacterial activity and reduced bacterial resistance: in vitro and in vivo evaluation. Expert Opinion on Drug Delivery 2015; 12(2): 163-80.
29. Abo Kamer AM, Amer NM, Abdelmegeed AA, Maghraby GM El, Gamaleldin NM. Surfactant nanovesicles for augmented antibacterial activity against carbapenemase resistant enterobacteriaceae and extended spectrum beta-lactamases producing bacteria: in vitro and in vivo evaluation. BMC Microbiol 2023; 23(1): 1-14.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
